Immunic, inc. announces results from interim safety analysis and recruitment update from its ongoing phase 2 calvid-1 trial of imu-838 in patients with moderate covid-19

Immunic, inc. announces results from interim safety analysis and recruitment update from its ongoing phase 2 calvid-1 trial of imu-838 in patients with moderate covid-19.immunic inc - to date, 110 patients have been enrolled in calvid-1 trial and enrollment is progressing well.immunic inc - independent data monitoring committee (idmc) has concluded that study should continue without changes.immunic inc - trial is expected to initially enroll about 230 patients at 10-35 centers across europe and u.s..immunic - plan to report results of pre-planned unblinded interim analysis of all available efficacy, biomarker and virus titer data later this year.
IMUX Ratings Summary
IMUX Quant Ranking